| Today’s Big NewsFeb 28, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
| By Angus Liu A new policy from President Donald Trump aims to restrict both inbound and outbound investments related to China in certain strategic industries, including biotechnology. |
|
|
|
By Darren Incorvaia The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion to develop new versions of the sticky molecules in collaboration with Magnet Biomedicine. |
By Conor Hale The cryoablation devicemaker Adagio Medical has opted to pause the European launch of one of its catheters, currently in the early stages, and will instead focus efforts on obtaining approval in the U.S. |
By Andrea Park Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT Softgels have emerged as a versatile dosage form, yet they are often overlooked. This webinar will explore the role of softgels in both early-stage and post-approval lifecycle management strategies. Learn about key considerations for launching with softgels, opportunities for post-approval switches to or from softgels, and how softgels compare to other dose forms. Register now. 
|
|
By Darren Incorvaia ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in mice with Huntington’s disease by more than 80%. |
By Kevin Dunleavy During a quarterly conference call, as Apellis Pharmaceuticals discussed its plan to increase sales of GA treatment Syfovre, it stressed the importance of attracting more patients to the market, including through a DTC campaign starring Henry Winkler. |
By James Waldron For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. While interest in this path has died down in recent years, BridgeBio’s former cancer unit thinks it could work for them. |
By Andrea Park Despite falling business interest in environmental, social and governance policies and outright opposition to such sustainability and ethics commitments in the U.S., company ESG practices still matter to patient groups’ perceptions of Big Pharma. |
By Kevin Dunleavy For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed that she took a 16% pay cut in 2024, it also laid out a new compensation plan which could make her one of the highest-paid chief executives in the industry this year. |
By Nick Paul Taylor Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after Praxis CEO Marcio Souza said the chances of the trial being futile were “less than 3%,” the biotech has learnt the study looks unlikely to meet its primary endpoint at an interim analysis. |
By Nick Paul Taylor Rare Disease Day 2025 triggered a flurry of pharma marketing activity, with Arrowhead Pharmaceuticals, Zevra Therapeutics and a clutch of other drug developers publishing materials to mark the event. |
By Fraiser Kansteiner Europe's Committee for Medicinal Products for Human Use recommended four new drugs for approval, teed up another 16 potential label expansions and—in a major win for Eisai and Biogen—reaffirmed the positive opinion on the Alzheimer’s disease drug Leqembi it first issued in November. |
By Darren Incorvaia,Zoey Becker Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a buyout that went for $3 per share. Mirati and Ipsen’s former CEO David Meek, who currently chairs Sobi, will take the reins at bluebird upon the deal’s close, which is expected to be in the first half of this year. |
By Angus Liu Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. Pfizer has formed a clinical trial collaboration with Akeso's partner Summit Therapeutics. And more. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
|
|---|
|
|
|
Tuesday, March 4, 2025 | 2pm ET / 11am PT Learn expert strategies for overcoming the unique challenges of early phase clinical trials, from preparing investigational products to maintaining blinding and sourcing controlled substances. This webinar provides actionable insights to optimize pharmacy activities and ensure trial success. Register now. 
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
